Sickle Cell Care for the General Pediatrician

Once a fatal illness of childhood, sickle cell disease (SCD) is now a chronic condition that children survive into adulthood — largely because of preventive care that begins in the primary care setting. This reference distills the evidence-based steps a general pediatrician can take to keep children with SCD healthy, recognize emergencies early, and connect families to Louisiana's sickle cell network, especially when a comprehensive center is hours away.

DownloAd the Presentation

Sickle Cell Disease in Louisiana

Roughly 100,000 people live with SCD in the United States, with a birth incidence of about 1 in 365 African-American and 1 in 16,300 Hispanic-American live births; sickle cell trait is carried by about 9% of the African-American population. Louisiana carries one of the highest per-capita SCD burdens in the country.

~80LA infants born with SCD each year

3,000Louisianans living with SCD

~1,400Pediatric patients (<18 yrs)

52.6Average life expectancy (years)

Pathophysiology in Brief

A single amino-acid substitution produces hemoglobin S. When deoxygenated, HbS polymerizes into long, stiff chains that deform red cells into the characteristic sickle shape. These rigid cells hemolyze early and lodge in the microvasculature, driving vaso-occlusion, endothelial dysfunction, and chronic inflammation — the cascade behind nearly every clinical complication.

The sickle cell cascade: polymerization → sickling → hemolysis and vaso-occlusion → endothelial injury and inflammation.

Genotypes and Severity

SCD severity tracks closely with genotype. Knowing a patient's type guides expected baseline hemoglobin and the intensity of monitoring required.

Type	Hemoglobin (g/dL)	Clinical features
Sickle cell trait (SCT)	13–18	Asymptomatic; extreme exercise in high heat may provoke hematuria.
Sickle cell β⁺-thalassemia	10–14	Rare crises; HbA production yields milder severity.
Sickle cell hemoglobin C (HbSC)	10–12	Mild anemia; hematuria; vaso-occlusive crises less common; complications more frequent in older patients.
Sickle cell β⁰-thalassemia	7–10	Severity similar to HbSS; no HbA production.
Sickle cell anemia (HbSS)	7–10	Increased incidence of vaso-occlusive crises; chronic anemia; microvascular organ injury common.

Multi-System Complications

SCD affects nearly every organ system. Vaso-occlusive crises and chronic pain are the common threads running through them.

Organ systems affected by SCD, all converging on vaso-occlusion and chronic pain.

The Newborn Screen: First Steps (FS Result)

A hemoglobinopathy screen reading FS indicates sickle cell anemia (HbSS) or Sβ⁰-thalassemia. Even when the nearest comprehensive center is hours away, the general pediatrician initiates care and education right away.

Refer to a comprehensive sickle cell center.
Counsel the family on pathophysiology and inheritance.
Teach fever precautions (see below) and the signs of pain, dactylitis, and splenomegaly.
Start penicillin prophylaxis and stay current on vaccinations.
Connect the family with local sickle cell support resources.

Fever thresholds requiring urgent evaluation: ≥ 101.3°F (38.5°C) in children older than 2 months; ≥ 100.4°F (38.0°C) in infants younger than 2 months.

Preventing Invasive Pneumococcal Infection

Functional asplenia can develop as early as 4 months of age, leaving children vulnerable to overwhelming pneumococcal sepsis. Penicillin prophylaxis reduced the incidence of invasive pneumococcal infection by 84% in the landmark Gaston (1986) trial — yet adherence remains a gap, with only 18% of children receiving at least 300 days of antibiotics in one analysis (Reeves, 2018).

Parameter	Recommendation
When to start	By 2 months of age in ALL patients with SCD.
Dose	Penicillin 125 mg twice daily if <3 years; 250 mg twice daily if ≥3 years.
How long	Until age 5 with all necessary vaccines completed; indefinitely if splenectomy or prior bacteremia.

Immunizations

Children with SCD need the routine schedule plus additional pneumococcal and meningococcal protection.

Pneumococcal

Pneumococcal conjugate vaccine (PCV / Prevnar): invasive pneumococcal disease fell by 86% after PCV13 introduction.
PPSV23 boosts the response to PCV serotypes — give after age 2, then boost in 3–5 years.
PCV20 may provide broader coverage: a 4-dose primary series, then a single dose at least 8 weeks after the last PCV (or 5 years after the last PPSV23).

Meningococcal

Vaccine	Schedule
Quadrivalent (ACWY) — Menactra or Menveo (not MenQuadfi)	2 doses 8 weeks apart starting at 24 months. Boosters: if first dose <7 yrs, 3 yrs after the primary series then every 5 yrs; if ≥7 yrs, 5 yrs after then every 5 yrs.
Serogroup B — Trumenba	3-dose series at 0, 2, and 6 months, starting at age 10.
Serogroup B — Bexsero	2-dose series 1 month apart, starting at age 10; boost 1 year later then every 2–3 yrs.

Schedules reflect the source presentation (2024). Confirm against current ACIP / AAP recommendations before applying, as immunization guidance is updated frequently.

Fever and Splenic Sequestration

Fever in a child with SCD is a medical emergency until proven otherwise.

Every patient with fever > 38.5°C needs a sepsis workup.
Draw a blood culture and give ceftriaxone as soon as possible.
Urine culture, chest X-ray, abdominal ultrasound, and viral studies must not delay antibiotics.
Admit children younger than 2 years or those with other high-risk features.

Splenic sequestration is an emergency. Suspect it with a drop in hemoglobin ≥ 2 g/dL, splenomegaly, and hemodynamic instability. Transfuse packed red cells in small aliquots (5–10 mL/kg) to avoid hyperviscosity. Consider splenectomy after more than two episodes requiring transfusion.

Vaso-Occlusive Crisis (VOC / VOE) and Pain

Vaso-occlusive events most often strike the extremities, chest, and back. Risk rises with higher HbS and lower fetal hemoglobin (HbF); common triggers include infection, dehydration, extreme temperatures, hypoxia, and stress. There is no test that rules a VOC in or out — and provider bias can interfere with care.

Pain management must be guided by the patient's own report of severity.

Acute pain

Scheduled NSAIDs plus opioids (oral or IV).
Conservative fluid administration.
Heat, lidocaine patches, topical NSAIDs, distraction, early ambulation.

Chronic pain & prevention

Pharmacologic care, psychosocial support, pain specialists, physical therapy.
Minimize triggers and encourage fluid intake.
Use disease-modifying agents.

Acute Chest Syndrome

Acute chest syndrome (ACS) is the leading cause of death in SCD. Its etiology is multifactorial — infection (29%), pulmonary infarction (16%), and fat embolism (9%) among the documented causes. Risk climbs during acute illness, severe VOC, and after general anesthesia.

Diagnosis

A new infiltrate on chest X-ray plus one or more of: fever > 38.5°C, hypoxia, respiratory changes, chest pain, or abnormal lung sounds. Presentation ranges from mild pneumonia to acute respiratory failure.

Management

Antibiotics: cephalosporin plus a macrolide.
Maintain oxygen saturation > 92%; incentive spirometry.
Cautious hydration.
Transfuse if > 1 g/dL below baseline.
Consider bronchodilators; avoid steroids.

Stroke Prevention and Screening

Stroke in SCD results from cerebrovascular occlusion of the internal carotid or middle cerebral artery, presenting as headache, hemiparesis, paresthesia, aphasia, or visual disturbance. About 10% of children with SCD will have a stroke by age 20 — which makes screening essential.

Primary prevention

Transcranial Doppler (TCD) yearly, ages 2–16, for HbSS or Sβ⁰.
Elevated TCD (> 200 cm/sec): refer for chronic transfusion therapy.
TWiTCH trial: hydroxyurea non-inferior to chronic transfusion.

Secondary prevention

Chronic transfusion therapy every 3–4 weeks.
Maintain HbS concentration below 30%.

Other routine screening

System	Screening
Retinopathy	Ophthalmology screening yearly starting at age 8.
Nephropathy	Blood pressure at every visit; random urine microalbumin/creatinine ratio yearly from age 10; refer to nephrology if abnormal on more than one occasion.
Cardiovascular	Regular BP and oxygen-saturation monitoring; ECG and echocardiogram as needed.
Cholelithiasis	Abdominal ultrasound as needed.

Disease-Modifying Therapy

Hydroxyurea

Hydroxyurea decreases pain crises, acute chest syndrome, blood transfusions, and mortality. The BABY HUG trial supports starting it in HbSS and Sβ⁰ infants as early as 9 months of age, given once daily starting at 20 mg/kg/day. It raises HbF, MCV, and total hemoglobin while lowering WBC, ANC, and reticulocyte counts; its toxicity is dose-dependent and reversible.

Other agents

Agent	Approved age
Voxelotor (Oxbryta)	Ages 4+
Crizanlizumab (Adakveo)	Ages 16+
L-glutamine (Endari)	Ages 5+
Folic acid	No longer recommended

Approvals and availability of disease-modifying agents change; voxelotor in particular has been subject to a manufacturer market withdrawal since this 2024 talk. Verify current status before prescribing.

Curative therapies

Stem cell transplant remains the established curative option, now joined by gene therapies — LentiGlobin (lentiviral) and exagamglogene autotemcel / exa-cel (CRISPR). Selecting the right candidate is complex and is best coordinated through a comprehensive center.

Sickle Cell Trait

About 3 million people in the U.S. carry sickle cell trait. It is mostly asymptomatic, though extreme conditions can provoke pain, splenic infarct, or rhabdomyolysis, and there is some risk of glaucoma and kidney disease. Compound heterozygosity matters for family planning, so counseling is appropriate.

Sudden death in sickle cell trait is very rare and should not exclude anyone from sports. Athletes with SCT can participate safely with simple precautions: stay hydrated, take breaks, and ease into new exercise programs.

Louisiana Sickle Cell Clinics

Louisiana maintains a statewide network of sickle cell clinics. When a comprehensive center is far away, these sites — and the center's telephone line — are the general pediatrician's partners in care.

Clinic	Location
LSU & Tulane / Children's Hospital Comprehensive Clinic	New Orleans
Sickle Cell Center of Southern LA (Adult / Transition) — Tulane	New Orleans
Ochsner Foundation Hospital	New Orleans
Moss Memorial Health Clinic	Lake Charles
St. Jude Children's Research Hospital Affiliate Clinic	Baton Rouge
Our Lady of the Lake Adult Sickle Cell Clinic	Baton Rouge
Children's Hospital Specialty Clinic	Lafayette
Ochsner Health Center for Children	Lafayette
Women's and Children's Rapides Specialty Clinic	Alexandria
Willis-Knighton Health Specialists	Shreveport
Ochsner LSU Health — Feist-Weiller Cancer Center	Shreveport
Monroe Sickle Cell Center	Monroe

Statewide Resources & Regional Foundations

The Louisiana Department of Health runs state newborn screening and publishes toolkits for schools and emergency departments. The Louisiana Sickle Cell Commission works "to ensure adequate services to all persons living with SCD and formulate new actions to reduce the burden of SCD in Louisiana," offering patient navigation, state advocacy, and a SCD registry. Regional foundations provide local support:

Region	Foundation	Location
Region 2	Baton Rouge Sickle Cell Association of South Louisiana	Baton Rouge, LA
Region 5	Etta Pete Sickle Cell Anemia Foundation, LLC	Lake Charles, LA
Region 6	Sickle Cell Anemia Research Foundation, Inc.	Alexandria, LA
Region 7	Sickle Cell Disease Association of America, Northwest Louisiana Chapter	Shreveport, LA
Region 8	Northeast Sickle Cell Anemia Foundation	Monroe, LA

The Sickle Cell Center as Your Hub

Think of the comprehensive sickle cell center as the hub of a wheel: the general pediatrician, the family, regional clinics, and foundations are the spokes, all connected through the center. When in doubt, call.

The comprehensive SCD center coordinates care across every partner in a child's circle.

Children's Hospital of New Orleans Sickle Cell Treatment Program — 504-896-9740

Action Items for the General Pediatrician

Ensure every patient with SCD is on penicillin prophylaxis until at least age 5 and up to date on all recommended vaccines.
Refer patients for transcranial Dopplers between ages 2 and 16 if they are not already followed at a sickle cell center.
Consider starting hydroxyurea — and know how to monitor it — when regular hematology follow-up isn't feasible.
Treat fever urgently and recognize acute chest syndrome and splenic sequestration as emergencies.
Keep families connected to Louisiana's clinics, foundations, and the comprehensive center.

Adapted from Sickle Cell Care for the General Pediatrician, presented by Molly Sonenklar, MD, MPH (Assistant Professor, Pediatric Hematology/Oncology; Assistant Director, Sickle Cell Treatment Program, LSU Health Sciences Center / Children's Hospital of New Orleans) at CENLA Potpourri, 2024. Selected source figures are omitted because of third-party copyright. This material is for clinician education and does not indicate an exclusive course of treatment or serve as a standard of medical care; variations accounting for individual circumstances may be appropriate. Verify immunization schedules and disease-modifying drug approvals against current ACIP, AAP, and FDA guidance before applying.